| Literature DB >> 30286799 |
Jiannan Li1, Zhao Cui1, Jian-Yan Long2, Wei Huang3, Jin-Wei Wang1, Haibo Wang2,4, Luxia Zhang1,5, Min Chen1, Ming-Hui Zhao6,7.
Abstract
BACKGROUND: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of life-threatening autoimmune diseases. The epidemiological data on AAV in China are limited. The aim of the present study is to investigate the frequency, geographical distribution, and ethnic distribution of AAV in hospitalized patients in China, and its association with environmental pollution.Entities:
Keywords: ANCA; Frequency; Hospitalized population; Vasculitis
Mesh:
Substances:
Year: 2018 PMID: 30286799 PMCID: PMC6235226 DOI: 10.1186/s13075-018-1708-7
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Demographic information on patients with AAV in 2015 in China
| AAV | GPA | MPA | EGPA | |
|---|---|---|---|---|
| Number | 4440 | 385 | 396 | 223 |
| Age (years) | 60.0 ± 15.6 | 50.7 ± 15.6 | 62.3 ± 17.2 | 50.3 ± 15.6 |
| Age group, % | ||||
| 0–17 | 1.3 | 1.6 | 3.5 | 3.1 |
| 18–30 | 5.0 | 11.4 | 2.8 | 9.4 |
| 31–40 | 4.8 | 10.4 | 2.8 | 11.2 |
| 41–50 | 11.8 | 23.9 | 7.4 | 20.2 |
| 51–60 | 20.6 | 24.4 | 17.4 | 27.8 |
| 61–70 | 29.9 | 17.1 | 34.8 | 21.5 |
| > 80 | 26.6 | 11.2 | 31.3 | 6.6 |
| Male, % | 46.4(45.0,47.9) | 49.9(44.9,54.9) | 48.5(43.6,53.4) | 52.5(45.9,59.0) |
| Occupation, % | ||||
| Professional or semi-professional | 9.1 (8.2,10.0) | 14.7 (10.9,18.4) | 8.5 (5.6,11.4) | 16.1 (11.1,21.1) |
| Worker | 2.9 (2.4,3.4) | 2.9 (1.1,4.6) | 2.5 (0.9,4.2) | 3.9 (1.3,6.6) |
| Farmer | 25.7 (24.3,27.0) | 22.4 (18.0,26.8) | 25.4 (20.9,30.0) | 22.0 (16.3,27.6) |
| Retired | 20.4 (19.1,21.6) | 12.9 (9.4,16.5) | 24.3 (19.8,28.8) | 15.6 (10.6,20.6) |
| Unemployed | 7.2 (6.4,8.0) | 6.9 (4.2,9.6) | 7.9 (5.1,10.7) | 4.4 (1.6,7.2) |
| Others | 34.7 (33.3,36.2) | 40.2 (35.1,45.4) | 31.4 (26.5,36.2) | 38.0 (31.4,44.7) |
| Medical insurance | ||||
| Basic Medical Insurance | 44.4 (43.0,45.9) | 38.2 (33.3,43.0) | 44.4 (39.6,49.3) | 45.7 (39.2,52.3) |
| New Rural Co-operative Medical Care | 24.1 (22.9,25.4) | 24.7 (20.4,29.0) | 21.7 (17.7,25.8) | 25.1 (19.4,30.8) |
| Other insurance | 16.0 (14.9,17.1) | 16.1 (12.4,19.8) | 21.5 (17.4,25.5) | 17.9 (12.9,23.0) |
| No insurance | 15.4 (14.4,16.5) | 21.0 (17.0,25.1) | 12.4 (9.1,15.6) | 11.2 (7.1,15.4) |
| Admission place | ||||
| Emergency | 12.6 (11.6,13.6) | 15.0 (11.3,18.7) | 11.5 (8.2,14.7) | 16.4 (11.5,21.4) |
| Routine | 79.9 (78.7,81.1) | 76.7 (72.3,81.0) | 83.1 (79.2,86.9) | 77 (71.3,82.6) |
| Other | 7.5 (6.7,8.3) | 8.3 (5.5,11.2) | 5.5 (3.1,7.8) | 6.6 (3.2,9.9) |
| ICU stay, % | 2.2 (1.7,2.6) | 0.3 (0,0.8) | 3.5 (1.7,5.4) | 0.4 (0,1.3) |
| Costs (10,000 RMB), median (Q1–Q3) | 13 (7–23) | 10 (6–19) | 14 (8–24) | 11 (7–18) |
| Length of stay (days), median (Q1–Q3) | 12 (8–19) | 12 (7–18) | 13 (8–21) | 12 (8–16) |
| In-hospital mortality, % | 1.8 (1.4,2.2) | 1.3 (0.2,2.4) | 2.8 (1.2,4.4) | 0.4 (0,1.3) |
Abbreviations: AAV anti-neutrophil cytoplasmic autoantibody associated vasculitis, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, EGPA eosinophilic granulomatosis with polyangiitis, ICU intensive care unit, RMB Renminbi, which is Chinese currency.
Fig. 1The distribution of anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) in different seasons in 2015. The highest frequency of admissions for AAV were in winter (30.2%)
Fig. 2The age distribution of anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) in 2015. Most patients with AAV were older than 50 years, with a peak age at 61–70 years (29.9%)
Fig. 3The distribution of anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) according to Chinese geographical regions in 2015. The frequency of AAV in all inpatients in seven geographical regions, with the highest in North China (0.44‰)
Fig. 4Ethnic distribution of anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) in the Chinese population. The Dong, Zhuang and Li ethnic minorities had the highest frequencies of AAV, with a frequency of 0.67‰, 0.61‰ and 0.42‰, respectively. HQMS, Hospital Quality Monitoring System
Fig. 5The proportion of anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) in Yunnan province and the national average value since 2013. The frequency of AAV in Yunnan province has increased annually since 2013
The International Classification of Diseases-10 coding of AAV
| Disease | ICD-10 coding |
|---|---|
| AAV | M31.802 |
| MPA | M31.701# |
| GPA | M31.301, K13.407# |
| EGPA | M30.101 |
#Applicable for ICD-10 (Beijing Version 4.0) only
†Applicable for ICD-10 (National Standard Version1.0) only
Abbreviations: ICD-10 International Classification of Diseases-10, AAV anti-neutrophil cytoplasmic autoantibodies associated vasculitis, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, EGPA eosinophilic granulomatosis with polyangiitis
The International Classification of Diseases-10 coding of exclusion criteria of AAV and complications
| Disease | ICD-10 coding |
|---|---|
| TAK | M31.401 |
| GCA | M31.501#, M31.601# |
| PAN | M30.002# |
| KD | M30.301# |
| RA | M05.391#, M05.392#, M06.811#, M06.821#, |
| SLE | F06.921#, M32.001#, M32.101 + G05.8*#, M32.102 + I32.8*#, M32.104 + J99.1*#, M32.105 + N08.5*#, M32.107 + J99.1*#, M32.108 + G63.5*#, M32.109 + G99.2*#, M32.110 + G63.5*#, M32.111 + K67.8*#, M32.112 + N08.5*#,,M32.113 + N16.4*#, M32.901# |
| Sarcoidosis | D86.001#, D86.301#, D86.102#, D86.201#, D86.301#, D86.802 + G53.2*#, D86.803 + H22.1*#, D86.804 + M63.3*#, D86.805 + I41.8*#, D86.806 + M14.8*#, D86.901#, K13.408# |
| IBD | K50.002, K50.003#, K50.004#, K50.005#, K50.006#, K50.101, K50.102, K50.103, K50.104, K50.803#, K50.901#, K50.902 + M07.4*#, K51.001#, K51.002, K51.201#, K51.301, K51.901, K51.902, K51.903 + M07.5*# |
| LVV | I77.601#; I77.602#; I77.603#; I77.604# |
| HBV | 54.808#, B18.102#, B18.103#, B18.104#, B18.105#, B18.106#, Z22.501#, Z22.502#, B16.001#, B16.002#, B16.101#, B16.103#, B16.104#, B16.105#, B16.201#, B16.202#, B16.901#, B16.902#, B16.903#, B16.905#, B18.004#, B18.005#, B18.006#, B18.101#, B18.102#, B18.103#, B18.104#, B18.105#, B18.106# |
| HCV | O98.402#, Z22.591#, B17.101#, B17.102#, B17.103#, B17.104#, B17.105#, B18.201#, B18.202#, B18.203#, B18.205#, B18.207#, B18.208# |
| Syphillis | A51, A52 |
| Carcinoma | C00-D49 |
| RPGN | N01.701#, N01.803#, N01.901#, N01.902#, N01.903# |
| Acute nephritis syndrome | N00.901#, N00.902#, N00.903#, N00.801#, N17.002#, N17.102#, N17.201#, N17.901#, N17.902#, N17.903#, N17.904# |
| NS | N04 |
#Applicable for ICD-10 (Beijing Version 4.0) only
†Applicable for ICD-10 (National Standard Version1.0) only
Abbreviations: ICD-10 International Classification of Diseases-10, TAK Takayasu arteritis, GCA giant cell arteritis, PAN polyarteritis nodosa, KD Kawasaki disease, LVV large vessel vasculitis, IBD inflammatory bowel disease, SLE systemic lupus erythematosus, RA rheumatoid arthritis, NS nephrotic syndrome, RPGN rapidly progressive glomerulonephritis